+

WO2001098359A3 - Cyr61 utilise comme cible dans le traitement et le diagnostic du cancer du sein - Google Patents

Cyr61 utilise comme cible dans le traitement et le diagnostic du cancer du sein Download PDF

Info

Publication number
WO2001098359A3
WO2001098359A3 PCT/US2001/019823 US0119823W WO0198359A3 WO 2001098359 A3 WO2001098359 A3 WO 2001098359A3 US 0119823 W US0119823 W US 0119823W WO 0198359 A3 WO0198359 A3 WO 0198359A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyr61
methods
breast cancer
diagnosis
target
Prior art date
Application number
PCT/US2001/019823
Other languages
English (en)
Other versions
WO2001098359A2 (fr
Inventor
Deepak Sampath
Zhiming Zhang
Richard Winneker
Original Assignee
American Home Prod
Deepak Sampath
Zhiming Zhang
Richard Winneker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod, Deepak Sampath, Zhiming Zhang, Richard Winneker filed Critical American Home Prod
Priority to US10/312,459 priority Critical patent/US20040086504A1/en
Priority to AU2001271365A priority patent/AU2001271365A1/en
Publication of WO2001098359A2 publication Critical patent/WO2001098359A2/fr
Publication of WO2001098359A3 publication Critical patent/WO2001098359A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des procédés de prévention ou d'inhibition de la prolifération cellulaire du cancer du sein, sur des composés et des compositions qui interfèrent avec le stéroïde sexuel ou le bloquent, ainsi que la liaison du facteur de croissance au gène Cyr61 ou l'induction de ce gène. L'invention porte également sur des procédés de criblage des ligands qui régulent l'expression de la protéine Cyr61. Cette invention porte, en outre, sur des composés qui bloquent l'activité de Cyr61, sur des procédés de diagnostic et de détermination du stade des patients atteints de ce cancer, associés à une régulation supérieure de l'expression de Cyr61. Des méthodes de dosage et des kits sont également décrits.
PCT/US2001/019823 2000-06-21 2001-06-21 Cyr61 utilise comme cible dans le traitement et le diagnostic du cancer du sein WO2001098359A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/312,459 US20040086504A1 (en) 2001-06-21 2001-06-21 Cyr61 as a target for treatment and diagnosis of breast cancer
AU2001271365A AU2001271365A1 (en) 2000-06-21 2001-06-21 Cyr61 as a target for treatment and diagnosis of breast cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21318200P 2000-06-21 2000-06-21
US60/213,182 2000-06-21
US29151001P 2001-05-16 2001-05-16
US60/291,510 2001-05-16

Publications (2)

Publication Number Publication Date
WO2001098359A2 WO2001098359A2 (fr) 2001-12-27
WO2001098359A3 true WO2001098359A3 (fr) 2002-06-06

Family

ID=26907838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019823 WO2001098359A2 (fr) 2000-06-21 2001-06-21 Cyr61 utilise comme cible dans le traitement et le diagnostic du cancer du sein

Country Status (2)

Country Link
AU (1) AU2001271365A1 (fr)
WO (1) WO2001098359A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082258A1 (fr) * 2002-03-25 2003-10-09 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Utilisation de cyr61 pour le diagnostic d'une insuffisance renale aigue
WO2004091383A2 (fr) 2003-04-01 2004-10-28 Genzyme Corporation Modeles d'expression des cellules endotheliales mammaires
JP2004315480A (ja) * 2003-04-21 2004-11-11 Yoshiyuki Kakehi 前立腺疾患治療用医薬組成物
US7056674B2 (en) * 2003-06-24 2006-06-06 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2006089212A2 (fr) * 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 comme biomarqueur pour le diagnostic et le pronostic de cancers d'origine epitheliale
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
EP2540742A4 (fr) * 2009-12-04 2014-02-12 Shanghai Inst Of Immunology Anticorps monoclonaux de la protéine anti-cyr61 et utilisations de ceux-ci
WO2011107590A1 (fr) 2010-03-04 2011-09-09 Wolfgang Poller Cnn1 (cyr61) dans le traitement prophylactique et thérapeutique d'une maladie inflammatoire
DE102010010288A1 (de) 2010-03-04 2011-09-08 Wolfgang Poller CCN1 zur Prävention und Therapie von entzündlichen Erkrankungen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033995A2 (fr) * 1996-03-15 1997-09-18 Munin Corporation Molecules de signalisation de matrice extracellulaire
WO2001005353A2 (fr) * 1999-07-14 2001-01-25 Novo Nordisk A/S UTILISATION DE FVIIa OU D'UN ANTAGONISTE DE FACTEUR TISSULAIRE TF POUR REGULER L'EXPRESSION GENIQUE, ET MIGRATION CELLULAIRE OU CHIMIOTAXIE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033995A2 (fr) * 1996-03-15 1997-09-18 Munin Corporation Molecules de signalisation de matrice extracellulaire
WO2001005353A2 (fr) * 1999-07-14 2001-01-25 Novo Nordisk A/S UTILISATION DE FVIIa OU D'UN ANTAGONISTE DE FACTEUR TISSULAIRE TF POUR REGULER L'EXPRESSION GENIQUE, ET MIGRATION CELLULAIRE OU CHIMIOTAXIE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. SAMPATH ET AL.: "Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: Regulation by 17beta-estradiol and overexpression in human breast cancer.", ENDOCRINOLOGY, vol. 142, no. 6, June 2001 (2001-06-01), Philadelphia, PA, USA, pages 2540 - 2548, XP001053141 *
D. XIE ET AL.: "CYR61, an angiogenic inducer, is over-expressed and estrogen inducible in breast cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 41, March 2000 (2000-03-01), New York, NY, USA, pages 338, XP002194654 *
M. TSAI ET AL.: "Involvement of Cyr61, a ligand for an integrin, in breast cancer progression.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 40, March 1999 (1999-03-01), New York, NY, USA, pages 560, XP002194653 *
P. JAY ET AL.: "The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p.", ONCOGENE, vol. 14, 10 April 1997 (1997-04-10), pages 1753 - 1757, XP000619714 *

Also Published As

Publication number Publication date
WO2001098359A2 (fr) 2001-12-27
AU2001271365A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2003004989A3 (fr) Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein
WO2004046342A3 (fr) Nouvelles cibles geniques et ligands se liant a ces cibles dans le traitement et le diagnostic de carcinomes
WO2005115435A3 (fr) Methodes et compositions de lutte contre les maladies de la croissance foetale par modulation de la relaxine
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
WO2005100998A3 (fr) Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer
EP2258873A3 (fr) Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
WO2008146309A3 (fr) Variantes génétiques sur les chr 5p12 et 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2003009814A3 (fr) Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
WO2002097395A3 (fr) Utilisation de p-cadherine comme cible dans la therapie anticancereuse
WO2005123993A3 (fr) Profilage micromatriciel bactériophage de la réponse humorale à la maladie
WO2004080425A3 (fr) Composes polypeptidiques permettant d'inhiber l'angiogenese et la croissance tumorale
WO2001098359A3 (fr) Cyr61 utilise comme cible dans le traitement et le diagnostic du cancer du sein
WO2004078035A3 (fr) Profiles d'expression pour le cancer du sein et methodes d'utilisation
WO2002064839A3 (fr) Gene amplifie de l'hepsine associee au cancer
AU2003217397A1 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
AU2003242815A8 (en) Method for the characterisation of circulating tumour cells stemming from solid cancers
WO1999028461A3 (fr) Dispositif et procede d'induction de l'apoptose en faisant interferer des proteines de type bip
EP2275445A3 (fr) Anticorps anti-ephb4 pour inhiber l'angiogenese et la croissance tumorale
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2004045545A3 (fr) Compositions et procedes destines au traitement du cancer, au criblage des composants anticancereux presumes et a l'estimation de l'evolution du cancer
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
WO2005019475A3 (fr) Proteine 2 inductible par l'hypoxie (hig2), nouvelle cible therapeutique potentielle de l'hypernephrome (rcc)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EC EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EC EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10312459

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载